Icon (NASDAQ:ICLR) Releases FY 2025 Earnings Guidance

Key Points

• Icon (NASDAQ:ICLR) issued FY 2025 earnings guidance, forecasting an EPS range of 13.000-14.000 and revenue between $7.9 billion to $8.2 billion, surpassing consensus estimates.
• Brokerage upgrades include Evercore ISI raising its target price from $170.00 to $240.00 and Rothschild Redb changing its rating from "hold" to "strong-buy."
• Icon's stock has shown resilience with a market capitalization of $13.36 billion and the current trading price opens at $165.44, near its fifty-two week high of $310.54.

Icon (NASDAQ:ICLR - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 13.000-14.000 for the period, compared to the consensus earnings per share estimate of 13.020. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $8.0 billion.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ICLR. Evercore ISI lifted their price target on Icon from $170.00 to $240.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Truist Financial lifted their price target on Icon from $187.00 to $234.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Jefferies Financial Group lowered Icon from a "buy" rating to a "hold" rating and dropped their price target for the company from $220.00 to $175.00 in a research report on Tuesday, September 9th. Baird R W upgraded Icon from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Robert W. Baird lifted their price objective on Icon from $222.00 to $224.00 and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $216.67.

Icon Stock Performance

NASDAQ:ICLR traded up $4.15 during mid-day trading on Tuesday, hitting $174.61. 727,162 shares of the company traded hands, compared to its average volume of 1,285,801. The stock's fifty day moving average price is $168.33 and its 200-day moving average price is $157.34. Icon has a one year low of $125.10 and a one year high of $310.54. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35. The firm has a market cap of $14.10 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 2.59 and a beta of 1.20.

Icon (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The business had revenue of $2.02 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the previous year, the company posted $3.75 earnings per share. Icon's revenue for the quarter was down 4.8% on a year-over-year basis. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. Research analysts anticipate that Icon will post 13.38 earnings per share for the current fiscal year.

Institutional Trading of Icon

Several hedge funds have recently bought and sold shares of ICLR. WINTON GROUP Ltd bought a new stake in Icon during the second quarter valued at about $254,000. Daiwa Securities Group Inc. boosted its stake in shares of Icon by 19.3% in the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company's stock worth $4,094,000 after acquiring an additional 4,546 shares during the period. Frontier Capital Management Co. LLC boosted its stake in shares of Icon by 97.6% in the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company's stock worth $10,379,000 after acquiring an additional 35,253 shares during the period. Peapack Gladstone Financial Corp bought a new position in shares of Icon in the second quarter worth about $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company's stock worth $113,000 after acquiring an additional 289 shares during the period. Institutional investors own 95.61% of the company's stock.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.